Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: three years of follow-up.
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood.2020006449
Abstract: Inhibitors of Bruton's tyrosine kinase (BTK) have established therapeutic activity in patients with Waldenström macroglobulinemia (WM). Zanubrutinib, a potent and selective BTK inhibitor, was evaluated in a phase 1/2 study in patients with WM who… read more here.
Keywords: waldenstr macroglobulinemia; treatment; rate; zanubrutinib treatment ... See more keywords
Zanubrutinib for the treatment of lymphoid malignancies: Current status and future directions
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2023.1130595
Abstract: Zanubrutinib (BGB-3111, Brukinsa®, BeiGene) is a next-generation irreversible inhibitor of Bruton’s tyrosine kinase (BTK), developed by BeiGene in 2012 for the treatment of B-cell malignancies. It was designed to minimize off-target inhibition of TEC- and… read more here.
Keywords: safety; zanubrutinib treatment; lymphoid malignancies; zanubrutinib ... See more keywords